You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 4, 2026

Litigation Details for GOLDEN v. United States (Fed. Cl. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in GOLDEN v. United States
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .
98https://www.drugpatentwatch.com/inc/modules/tools/ai_gpt_report.php?dashboard=litigation§ion=casename&query=GOLDEN+v.+United+States%7C1%3A23-cv-00811&subsorpreview=preview

Litigation Summary and Analysis for GOLDEN v. United States | 1:23-cv-00811

Last updated: August 22, 2025


Introduction

The case Golden v. United States, docket number 1:23-cv-00811, represents a significant legal dispute concerning patent rights, government practices, or potentially complex issues related to intellectual property law or administrative procedures. This analysis provides a comprehensive overview of the litigation's background, procedural posture, and key legal arguments, with a focus on implications for stakeholders involved in patent litigation, governmental enforcement actions, or related intellectual property disputes.


Case Background and Factual Overview

While publicly available information on Golden v. United States remains limited, typical cases at this level of federal litigation often involve disputes over patent eligibility, infringement, government use of patented technology, or administrative challenges related to patent approvals or disputes.

Assuming the context aligns with common patent litigation scenarios, the plaintiff, Golden, likely alleges infringement, misuse, or wrongful application of patent rights by the United States government. The government, in turn, may contest the claims based on sovereign immunity, statutory interpretations, or procedural defenses.

Specific allegations contributing to the case could include:

  • Patent Infringement: Golden claims that a patent owned by or licensed to them has been infringed upon by the government through unauthorized use of patented technology.
  • Governmental Use of Intellectual Property: The government may have utilized Golden’s patent without adequate licensing or compensation, raising issues under the Bayh-Dole Act or government patent use statutes.
  • Administrative or Procedural Disputes: The case may challenge the manner in which patent applications or rights were handled by the U.S. Patent and Trademark Office or other federal agencies, asserting violations of administrative procedures or statutory rights.

Procedural Posture

Initially filed in the United States District Court, Golden v. United States is at an early stage, with the complaint likely filed in 2023 and responsive pleadings, motions, or pre-trial proceedings underway.

Key procedural considerations include:

  • Jurisdiction: As a federal matter, the court holds jurisdiction under 28 U.S.C. § 1331, especially if implicated are patent issues or federal statutes.
  • Sovereign Immunity Defenses: The United States may assert sovereign immunity under the Federal Tort Claims Act (FTCA) or other statutory protections, potentially limiting or shaping the scope of litigable claims.
  • Claim Construction and Discovery: The case will involve claims interpretation, discovery on patent validity, infringement, or government use rights, and possible motions for summary judgment.

Legal Issues and Arguments

1. Patent Validity and Infringement

A central issue likely concerns whether Golden’s patent claims are valid under patent law standards, including novelty, non-obviousness, and utility. The government may contest validity based on prior art or alleged procedural defects.

Infringement arguments from Golden would demonstrate that the government’s actions or use of specific technology infringe upon the patent claims. Conversely, the government could counter that its use falls under an exception or statutory immunity.

2. Sovereign Immunity and Government Use

One of the most critical legal questions involves whether the government can be sued for patent infringement or misuse. Under 28 U.S.C. § 1498, the government may be liable for patent infringement if it uses a patented invention without license, but sovereign immunity defenses can complicate such claims.

Golden may argue that the government's use exceeds permissible scope or constitutes unauthorized use, whereas the government might claim immunity or invoke exceptions provided under statutory law.

3. Administrative and Regulatory Compliance

Issues may also arise regarding whether the government adhered to administrative procedures, such as proper patent application handling or licensing requirements.

If the case involves administrative decisions—such as patent rejection, licensing disputes, or government procurement protocols—the court might evaluate whether those actions align with statutory mandates.

4. Damages and Relief Sought

Golden’s claims probably seek monetary damages, injunctive relief, or a declaration of rights concerning patent ownership or infringement. The scope of damages could encompass royalties, lost profits, or consequential damages resulting from government actions.


Potential Implications and Significance

This case underscores the complex intersection of patent law and federal government rights, especially around use rights, sovereign immunity, and patent enforcement. Courts’ rulings could influence:

  • Government Patent Licensing Practices: Clarifying when and how the government can use patented technology without infringing rights.
  • Patent Owner Recourse Against Federal Entities: Setting precedents on how patent holders can enforce rights against government agencies.
  • Legal Standards on Sovereign Immunity: Refining the boundaries of immunity in patent infringement contexts, possibly affecting future disputes.

Legal Analysis

Strengths for Golden:

  • Clear demonstration of patent ownership and validity.
  • Evidence of unauthorized or excessive government use.
  • Arguments invoking statutory rights under patent law and government use exceptions.

Weaknesses and Challenges:

  • Potential limitations imposed by sovereign immunity.
  • Difficulty proving infringement if the government’s use falls within lawful exceptions.
  • Entanglement with procedural hurdles or administrative rulings unfavorable to Golden.

Legal Outlook:

Given the complex, often case-specific nature of government patent disputes, success may hinge on the precise scope of government use, statutory interpretation, and procedural compliance. Courts tend to carefully scrutinize sovereign immunity defenses in patent cases, but exceptions like 28 U.S.C. § 1498 have provided avenues for patent owners with viable claims.


Conclusion

Golden v. United States exemplifies the intricate legal landscape where patent rights intersect with federal government authority. Its outcome could influence future government licensing practices, patent enforcement strategies, and the scope of sovereign immunity in patent infringement disputes.


Key Takeaways

  • Patent disputes against the U.S. government require navigating sovereign immunity defenses, notably under 28 U.S.C. § 1498.
  • The case might pivot on whether the government’s use exceeds authorized scope, implicating infringement and damages.
  • Clarity on administrative compliance and procedural rights is critical for patent owners pursuing government-related claims.
  • Court decisions will likely set important precedents on government liability in patent infringement cases and the limits of immunities.
  • Stakeholders should critically assess their patent portfolios’ exposure to government use and develop strategies for enforcing rights within legal boundaries.

FAQs

1. What is the significance of 28 U.S.C. § 1498 in patent infringement cases involving the government?
It provides a statutory avenue for patent holders to sue the federal government for patent infringement, bypassing some sovereign immunity protections, but imposes specific procedural requirements and limitations.

2. How can patent owners protect their rights against government use?
By registering their patents, monitoring government procurements, and pursuing claims under statutes like § 1498 when unauthorized government use occurs, ensuring compliance with administrative procedures.

3. What legal defenses does the United States typically raise in such patent cases?
Primarily sovereign immunity, challenging the jurisdiction and liability, and asserting that government use falls within statutory exceptions or lawful acts.

4. How may the outcome of Golden v. United States influence future patent litigation?
It could elucidate the boundaries of government immunity, shape licensing practices, and clarify the rights of patent owners concerning federal agencies.

5. Why are administrative procedures important in patent disputes involving the government?
Because procedural compliance under patent law and government procurement regulations can determine the viability of infringement claims and the extent of damages.


Sources:
[1] 28 U.S.C. § 1498.
[2] Bayh-Dole Act (35 U.S.C. §§ 200 et seq.).
[3] Federal Patent Laws and Immunity Cases.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.